Tolerability of riluzole: A review of the literature;Tollerabilità del riluzolo: Una revisione della letteratura

Clinica Terapeutica

Volumn 155, Issue 1, 2004, Pages 25-28

  Siniscalchi, Antonio ^a  

^a Azienda Ospedaliera di Cosenza   (Italy)

Author keywords

ASL; Riluzole; Tolerability

Indexed keywords

AMINOTRANSFERASE; GLUTAMATE RECEPTOR ANTAGONIST; RILUZOLE; AMINO ACID RECEPTOR BLOCKING AGENT;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; AMYOTROPHIC LATERAL SCLEROSIS; ANOREXIA; ASTHENIA; CIRCUMORAL PARESTHESIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG EFFICACY; DRUG TOLERABILITY; EXCITOTOXICITY; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL LITERATURE; NAUSEA; NERVE DEGENERATION; REVIEW; SOMNOLENCE; SURVIVAL; VERTIGO; VOMITING;

EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; RILUZOLE;

EID: 4043062932     PISSN: 00099074     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Brooks BR: El Escorial Word Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 124(suppl. 2): 94-107, 1994
2. de Belleroche J, Orrell RW, Virgo L: Amyotrophic lateral sclerosis: recent advances in understanding disease mechanisms. J Neuropathol Exp Neurol 55(7): 747-57, 1996
3. Brighina L, Sala G, Ceresa C, et al.: Recent advances in the therapy of amyotriphic lateral sclerosis: focus on excitotoxicity. Funct Neurol 16(suppl. 4): 189-202, 2001
4. Heath PR, Shaw PJ: Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve 26(4): 438-458, 2002
5. Leigh PN, Ray-Chaudhuri K: Motor neuron disease. J Neurol Neurosurg Psychiatry 57(8): 886-96, 1994
6. Rothstein JD, Tsai G, Kunel RW, et al.: Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 28: 18-25, 1990
7. Shaw PJ, Forrest V, Ince PG, et al.: CSF and plasma amino acid level in motor neurone disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration 4: 209-216, 1995
8. Niebroj-Dobosz I, Janik P, Kwiecinski H: Effect of riluzole on serum amino acids in patients with amyotrophic lateral sclerosis. Acta Neurologica Scandinava 106(1): 39-43, 2002
9. Bensimon G, Lacombez L, Meininger V: ASL/Riluzole study group: A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 330: 585-591, 1994
10. Lacombez L, Bensimon G, Leigh PN, et al.: ASL/Riluzole study group II. Lancet 25, 347: 1425-31, 1996
11. Miller RG, Bouchard JP, Duquette P, et al.: Clinical trials of riluzole in patients with ALS. Neurology 47(suppl. 2): S86-S92, 1996
12. Meininger V, Dib M, Aubin F, et al.: The riluzole early access profram: descriptive analysis of 844 patients in France. ASL/Riluzole study Group III. J Neurol 244: S22-S25, 1997
13. Wokke J: Riluzole. Lancet 348: 795-799, 1996
14. Siniscalchi A, Zona C, Sancesario G, et al.: Neuroprotective effects of riluzole: an electrophysiological and histological analysis in an in vitro model of ischemia. Synapse 32: 147-152, 1999
15. Cheramy A, Barbeito L, Godeheu G, et al.: Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo. Neurosci Lett 147: 209-212, 1992
16. Obrenovitch TP: Amyotrophic lateral sclerosis, excitotoxicity, and riluzole. Trends Pharmacol Sci 19: 9-11, 1998
17. Siniscalchi A, Bonci A, Mercuri NB, et al.: Effects of riluzole on rat cortical neurons: an in vitro electrophysiological study. Br J Pharmacol 120: 225-230, 1997
18. De Sarro GB, Siniscalchi A, Ferreri G, et al.: NMDA and AMPA/ kainate receptors are involved in the anticonvulsant activity of riluzole in DBA/2 mice. Eur J Pharmacol 408: 25-34, 2000
19. Zona C, Cavalcanti S, De Sarro GB, et al.: Kainate-induced currents in rat cortical neurons in culture are modulated by riluzole. Synapse 43(4): 244-251, 2002
20. Zona C, Siniscalchi A, Mercuri NB, et al.: Riluzole interacts with voltage-activated sodium and potassium currents in cultured rat cortical neurons. Neuroscience 85: 931-938, 1998
21. Stefani A, Spadoni F, Bernardi G: Differential inhibition by riluzole, lamotrigine, and phenytoin of sodium and calcium currents in cortical neurons: implications for neuroprotective strategies. Exp Neurol 147(1): 115-122, 1997
22. Lacombez L, Dib M, Doppler V, et al.: Tolerance of riluzole in a phase IIIb clinical trial. Therapie 57(1): 65-71, 2002
23. Castells LI, Gamez J, Cervera C, et al.: Icteric toxic hepatitis associated with riluzole. Lancet 351(9103): 648, 1998
24. Rhone-Puolenc Rorer. Riluzole prescribing information. Collegeville, PA, USA, 1996
25. Remy al, Camu W, Ramos J, et al.: Acute hepatitis after riluzole administration. J Hepatol 30(3): 527-530, 1999
26. Drody VE, Sidi I, Korczyn AD: Riluzole-induced pancreatitis. Neurology 52: 892-893, 1999
27. Rodrigo L, Moreno M, Calleja S, et al.: Riluzole-induced acute pancratitis. Am J Gastrenterol 96(7): 2268-2269, 2001
28. Production Information: RiluteK®, riluzole. Rhone-Poulenc Rorer Pharmaceuticals Inc, Collegeville, PA, PI revised 1/96 reviewed 3/2000
29. Scelsa SN, Khan I: Blood pressure elevations in riluzole-treated patients with amyotrophic lateral sclerosis. Eur Neurol 43(4): 224-227, 2000
30. North WA, Khan AM, Yamase HT, et al.: Reversible granulocytopenia in association with riluzole therapy. Ann Pharmacother 34: 322-324, 2000
31. Viallon A, Page Y, Bertrand JC: Methemoglobinemia due to riluzole. N Engl J Med 343(9): 665-666, 2000
32. Poloni TE, Alimonti D, Montagna G, et al.: Renal tubular impairment during riluzole therapy. Neurology 52 (letter): 670, 1999
33. Roch-Torreilles I, Camu W, Hillaire-Buys D: Adverse effects of riluzole (Rilutek) in the treatment of amyotrophic lateral sclerosis. Therapie 55(2): 303-312, 2000